PatentsGlobal
Xeris Biopharma Posts 81% Surge in Recorlev Sales as Keveyis Patent Protection Extended to 2039
Xeris Biopharma reported substantial year-over-year revenue growth for its Cushing’s syndrome treatment Recorlev in Q2 2026, driven by increased patient demand and strategic commercial investments. The company also secured a Notice of Allowance for a new Keveyis patent, potentially extending intellectual property prot…
Sunday, August 9, 2026